Organogenesis (NASDAQ:ORGO) Shares Down 3.7% After Insider Selling

Shares of Organogenesis (NASDAQ:ORGO) were down 3.7% during trading on Friday after an insider sold shares in the company. The company traded as low as $5.50 and last traded at $5.5550. Approximately 209,215 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 1,449,700 shares. The stock had previously closed at $5.77.

Specifically, Director Glenn H. Nussdorf sold 200,000 shares of Organogenesis stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $5.14, for a total value of $1,028,000.00. Following the completion of the sale, the director owned 2,565,591 shares in the company, valued at approximately $13,187,137.74. The trade was a 7.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Analysts Set New Price Targets

A number of equities analysts recently commented on ORGO shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organogenesis in a research note on Monday. BTIG Research reiterated a “buy” rating and issued a $9.00 target price on shares of Organogenesis in a research report on Monday. Finally, Wall Street Zen raised Organogenesis from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $8.00.

Organogenesis Price Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88. The stock has a market capitalization of $703.72 million, a price-to-earnings ratio of -46.29 and a beta of 1.47. The company has a 50-day simple moving average of $4.85 and a two-hundred day simple moving average of $4.49.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.07 by $0.11. The business had revenue of $150.86 million during the quarter, compared to analyst estimates of $134.10 million. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. On average, equities research analysts predict that Organogenesis will post -0.07 earnings per share for the current year.

Institutional Investors Weigh In On Organogenesis

A number of hedge funds have recently made changes to their positions in the business. Quarry LP bought a new position in Organogenesis in the 3rd quarter worth approximately $25,000. State of Alaska Department of Revenue acquired a new position in shares of Organogenesis during the third quarter valued at $25,000. Farther Finance Advisors LLC acquired a new stake in Organogenesis in the second quarter worth about $35,000. Ground Swell Capital LLC bought a new position in Organogenesis in the 2nd quarter valued at about $39,000. Finally, Regent Peak Wealth Advisors LLC acquired a new position in Organogenesis during the 3rd quarter valued at about $51,000. Institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.